300 related articles for article (PubMed ID: 32486414)
21. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.
Howlett EH; Jensen N; Belmonte F; Zafar F; Hu X; Kluss J; Schüle B; Kaufman BA; Greenamyre JT; Sanders LH
Hum Mol Genet; 2017 Nov; 26(22):4340-4351. PubMed ID: 28973664
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation.
Su YC; Qi X
Hum Mol Genet; 2013 Nov; 22(22):4545-61. PubMed ID: 23813973
[TBL] [Abstract][Full Text] [Related]
23. Molecular insights of the G2019S substitution in LRRK2 kinase domain associated with Parkinson's disease: A molecular dynamics simulation approach.
Agrahari AK; Doss GPC; Siva R; Magesh R; Zayed H
J Theor Biol; 2019 May; 469():163-171. PubMed ID: 30844370
[TBL] [Abstract][Full Text] [Related]
24. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA
Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990
[TBL] [Abstract][Full Text] [Related]
25. Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers.
Dzamko N; Rowe DB; Halliday GM
Mov Disord; 2016 Jun; 31(6):889-97. PubMed ID: 26917005
[TBL] [Abstract][Full Text] [Related]
26. Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice Through Activating TNF-α Pathway.
Lin CH; Lin HY; Ho EP; Ke YC; Cheng MF; Shiue CY; Wu CH; Liao PH; Hsu AY; Chu LA; Liu YD; Lin YH; Tai YC; Shun CT; Chiu HM; Wu MS
Mov Disord; 2022 Apr; 37(4):745-757. PubMed ID: 34918781
[TBL] [Abstract][Full Text] [Related]
27. LRRK2 impairs PINK1/Parkin-dependent mitophagy via its kinase activity: pathologic insights into Parkinson's disease.
Bonello F; Hassoun SM; Mouton-Liger F; Shin YS; Muscat A; Tesson C; Lesage S; Beart PM; Brice A; Krupp J; Corvol JC; Corti O
Hum Mol Genet; 2019 May; 28(10):1645-1660. PubMed ID: 30629163
[TBL] [Abstract][Full Text] [Related]
28. In Vitro CRISPR/Cas9-Directed Gene Editing to Model LRRK2 G2019S Parkinson's Disease in Common Marmosets.
Vermilyea SC; Babinski A; Tran N; To S; Guthrie S; Kluss JH; Schmidt JK; Wiepz GJ; Meyer MG; Murphy ME; Cookson MR; Emborg ME; Golos TG
Sci Rep; 2020 Feb; 10(1):3447. PubMed ID: 32103062
[TBL] [Abstract][Full Text] [Related]
29. In Vitro Modeling of Leucine-Rich Repeat Kinase 2 G2019S-Mediated Parkinson's Disease Pathology.
Vermilyea SC; Emborg ME
Stem Cells Dev; 2018 Jul; 27(14):960-967. PubMed ID: 29402177
[TBL] [Abstract][Full Text] [Related]
30. Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor.
Bright JM; Carlisle HJ; Toda AMA; Murphy M; Molitor TP; Wren P; Andruska KM; Liu E; Barlow C
Mov Disord; 2021 Jun; 36(6):1362-1371. PubMed ID: 33836114
[TBL] [Abstract][Full Text] [Related]
31. Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation.
Hermanson SB; Carlson CB; Riddle SM; Zhao J; Vogel KW; Nichols RJ; Bi K
PLoS One; 2012; 7(8):e43580. PubMed ID: 22952710
[TBL] [Abstract][Full Text] [Related]
32. Identification of Targets from LRRK2 Rescue Phenotypes.
Toh J; Chua LL; Ho P; Sandanaraj E; Tang C; Wang H; Tan EK
Cells; 2021 Jan; 10(1):. PubMed ID: 33466414
[TBL] [Abstract][Full Text] [Related]
33. LRRK2 functions in synaptic vesicle endocytosis through a kinase-dependent mechanism.
Arranz AM; Delbroek L; Van Kolen K; Guimarães MR; Mandemakers W; Daneels G; Matta S; Calafate S; Shaban H; Baatsen P; De Bock PJ; Gevaert K; Vanden Berghe P; Verstreken P; De Strooper B; Moechars D
J Cell Sci; 2015 Feb; 128(3):541–52. PubMed ID: 25501810
[TBL] [Abstract][Full Text] [Related]
34. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
Monfrini E; Di Fonzo A
Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276
[TBL] [Abstract][Full Text] [Related]
35. Impaired serine metabolism complements LRRK2-G2019S pathogenicity in PD patients.
Nickels SL; Walter J; Bolognin S; Gérard D; Jaeger C; Qing X; Tisserand J; Jarazo J; Hemmer K; Harms A; Halder R; Lucarelli P; Berger E; Antony PMA; Glaab E; Hankemeier T; Klein C; Sauter T; Sinkkonen L; Schwamborn JC
Parkinsonism Relat Disord; 2019 Oct; 67():48-55. PubMed ID: 31621607
[TBL] [Abstract][Full Text] [Related]
36. Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD activity and neurotoxicity in Parkinson's disease.
Chen ZC; Zhang W; Chua LL; Chai C; Li R; Lin L; Cao Z; Angeles DC; Stanton LW; Peng JH; Zhou ZD; Lim KL; Zeng L; Tan EK
Sci Signal; 2017 Jul; 10(488):. PubMed ID: 28720718
[TBL] [Abstract][Full Text] [Related]
37. Leucine rich repeat kinase 2 (LRRK2) GLY2019SER mutation is absent in a second cohort of Nigerian Africans with Parkinson disease.
Okubadejo NU; Rizig M; Ojo OO; Jonvik H; Oshinaike O; Brown E; Houlden H
PLoS One; 2018; 13(12):e0207984. PubMed ID: 30507963
[TBL] [Abstract][Full Text] [Related]
38. Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3β activity.
Lin CH; Lin HI; Chen ML; Lai TT; Cao LP; Farrer MJ; Wu RM; Chien CT
Hum Mol Genet; 2016 May; 25(10):1965-1978. PubMed ID: 26931464
[TBL] [Abstract][Full Text] [Related]
39. G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization.
Papkovskaia TD; Chau KY; Inesta-Vaquera F; Papkovsky DB; Healy DG; Nishio K; Staddon J; Duchen MR; Hardy J; Schapira AH; Cooper JM
Hum Mol Genet; 2012 Oct; 21(19):4201-13. PubMed ID: 22736029
[TBL] [Abstract][Full Text] [Related]
40. LRRK2 G2019S and Parkinson's disease: insight from Neuroinflammation.
Yao XY; Guan LN; Chen Q; Ren C
Postgrad Med J; 2023 Dec; 100(1179):4-11. PubMed ID: 37777187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
